A class of highly potent synthetic opioids that first appeared in Pennsylvania in 2019 will be classified in the state as having no acceptable medical use, Health Secretary Debra Bogen announced Friday.

The scheduling of drugs known as nitazenes, while temporary, is meant to address a substance that has contributed to 45 deaths in the commonwealth since 2023, according to a Department of Health news release.

“Substance use has taken the lives of far too many Pennsylvanians, and the Shapiro Administration is doing everything in its power to lower the number of people experiencing drug overdoses,” Ms. Bogen said. “Scheduling Nitazenes, which have no acceptable medical use, as Class I substances provides law enforcement with the authority to crack down on its possession and distribution in Pennsylvania.”

The scheduling went into effect Saturday.

Advertise with us

Nitazenes have been on the radar of the U.S. Food and Drug Administration and the Drug Enforcement Agency since at least 2021, as the agencies have seized pills that tested positive for the substance and aim to warn law enforcement about its lethality.

The move is part of a push from the Shapiro administration to crack down on the illicit drug market as it continues to shift and incorporate an array of new substances, often leading to wounds, severe withdrawal, overdose and death. In May 2024, the administration classified the veterinary sedative xylazine after it began showing up in the fentanyl supply.

As the Pennsylvania Department of Health works to permanently schedule nitazenes, harm reduction workers in Allegheny County and across the state are skeptical. Many noted that prevalence of nitazenes is sporadic and agreed that rescheduling a substance is not a feasible solution for curtailing drug use.

“We know that scheduling hasn’t made xylazine go away,” said Alice Bell, overdose prevention project coordinator at Prevention Point Pittsburgh. “That’s not an effective strategy, and it never has been. When it is, we usually see something worse coming up.”

Nitazenes are a class of synthetic opioid that were originally created in the second half of the 20th century as a possible alternative to morphine, but their development was halted after researchers found they had a high potential for abuse. Illicit versions of the drug were first identified in the U.S. in the Midwest in 2019, according to the DEA.

Advertise with us

But aside from sporadic sightings, nitazenes haven’t established a strong presence in the Pennsylvania drug supply, said those who work with people who use drugs and regularly test the illicit supply.

“It’s been seen in other places, but we haven’t seen it here,” said Ms. Bell. “It’s not an issue here at this point.”

Those in the field haven’t seen more than sporadic pockets of nitazenes on either side of the state, echoed Robert Ashford, executive director of the South Side-based recovery support group Unity Recovery.

Though not in large numbers, the substance has reached Western Pennsylvania. On Oct. 8, 2023, 41-year-old Anthony Gallaher died in West Mifflin of intoxication due to N-Desethyl Isotonitazene, a form of nitazene, according to a county medical examiner’s report.

And in the past two weeks, three patients have come into the Penn Highlands Healthcare Substance Recovery Unit withdrawing from nitazenes, said Amy Grey, a registered nurse at the Mon Valley-based hospital.

Advertise with us

Currently, harm reductionists are more focused on medetomidine, a sedative 200 times stronger than xylazine that has gained prevalence in the illicit supply.

The drug-checking group PA Groundhogs, along with the Center for Forensic Science Research & Education, tested drug samples from more than two dozen Pennsylvania counties between 2023 and 2025. In a recent report, they found that the amount of xylazine in samples tested declined significantly over the course of last year. At the same time, medetomidine’s presence shot up.

There’s now movement in the Pennsylvania Legislature to schedule medetomidine the same way. Harm reductionists insist it won’t work.

“While well-intentioned, we know from experience that scheduling one substance invariably leads to the introduction of new, often more dangerous alternatives to the drug supply,” said PA Groundhogs founder Chris Moraff in a collaborative statement with the Pennsylvania Harm Reduction Network.